Brighton Collaboration, Task Force for Global Health, Decatur, GA, USA; Global Health Program, College of Public Health, National Taiwan University, Taipei, Taiwan; National Taiwan University Children's Hospital, Taipei, Taiwan.
Brighton Collaboration, Task Force for Global Health, Decatur, GA, USA.
Vaccine. 2024 Nov 14;42(25):126131. doi: 10.1016/j.vaccine.2024.07.032. Epub 2024 Jul 12.
Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a newly recognized syndrome mediated by anti-platelet factor 4 antibodies induced by Covid-19 adenovirus-vectored vaccines including ChAdOx1 nCoV-19 and Ad26.COV2.S. This study validated a proposed Brighton Collaboration case definition for VITT. A data collection form was developed and used to capture the variations in VITT criteria and assess their level of diagnostic certainty from adjudicated positive VITT case datasheets in Germany (n = 71), UK (n = 220), Australia (n = 203), and Taiwan (n = 56). We observed high prevalence of each component of the proposed VITT definition in positive cases (84%-100%), except for the occurrence of thrombosis or thromboembolism criterion in only 34% of VITT cases in Taiwan. The sensitivity of this proposed definition was 100% for Germany and UK, 92% for Australia, and 89% for Taiwan cases. These findings support the validity of this case definition for VITT.
疫苗诱导的免疫性血小板减少症和血栓形成（VITT）是一种新发现的综合征，由 COVID-19 腺病毒载体疫苗（包括 ChAdOx1 nCoV-19 和 Ad26.COV2.S）诱导的抗血小板因子 4 抗体引起。本研究验证了布莱顿合作组织提出的 VITT 病例定义。制定了一份数据收集表，用于从德国（n=71）、英国（n=220）、澳大利亚（n=203）和中国台湾（n=56）的经裁决的阳性 VITT 病例数据表中捕捉 VITT 标准的变化，并评估其诊断确定性水平。我们观察到阳性病例中提出的 VITT 定义的每个组成部分的高患病率（84%-100%），但在台湾的 VITT 病例中，只有 34%出现血栓形成或血栓栓塞标准。该定义在德国和英国的敏感性为 100%，在澳大利亚为 92%，在中国台湾为 89%。这些发现支持该 VITT 病例定义的有效性。
